David Burns
Overview
Explore the profile of David Burns including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
5623
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nagler A, Labopin M, Salmenniemi U, Wu D, Blaise D, Rambaldi A, et al.
Bone Marrow Transplant
. 2024 Aug;
59(11):1563-1576.
PMID: 39164484
We assessed outcomes of allogeneic transplantation (HSCT) in favorable risk AML in CR1 over 3 time periods. 1850 patients were included, 2005 to 2009- 222, 2010 to 2014 -392, and...
12.
Styczynski J, Tridello G, Knelange N, Wendel L, Ljungman P, Mikulska M, et al.
Bone Marrow Transplant
. 2024 Jul;
59(10):1402-1412.
PMID: 38987308
The objective of the study was the analysis of clinical types, outcomes, and risk factors associated with the outcome of adenovirus (ADV) infection, in children and adults after allo-HCT. A...
13.
OReilly M, Wilson W, Burns D, Kuhnl A, Seymour F, Uttenthal B, et al.
Hemasphere
. 2024 Jun;
8(6):e87.
PMID: 38873532
Brexucabtagene autoleucel (brexu-cel) is an autologous CD19 CAR T-cell product, approved for relapsed/refractory (r/r) mantle cell lymphoma (MCL). In ZUMA-2, brexu-cel demonstrated impressive responses in patients failing ≥2 lines, including...
14.
Nagler A, Ngoya M, Galimard J, Labopin M, Blau I, Kroger N, et al.
Am J Hematol
. 2024 Jun;
99(9):1732-1745.
PMID: 38856236
We compared relapse incidence (RI) post-unrelated transplantation with post-transplant cyclophosphamide (PTCy) versus no PTCy graft-versus-host disease (GVHD) prophylaxis, in 7049 acute myeloid leukemia (AML) patients in remission, 707 with PTCy,...
15.
Cappuccio J, Osman K, Burns D
Clin J Gastroenterol
. 2024 May;
17(4):765-770.
PMID: 38775908
Extra pancreatic manifestations of pancreatitis are rare, with a prevalence of 2-3%. One such rare manifestation is the triad of joint pain (polyarthritis), tender skin lesions (panniculitis), and pancreatic inflammation...
16.
Ye Y, Labopin M, Gerard S, Yakoub-Agha I, Blau I, Aljurf M, et al.
Am J Hematol
. 2024 Apr;
99(7):1290-1299.
PMID: 38654658
Allogeneic hematopoietic cell transplantation (allo-HCT) is recommended for core-binding factor mutated (CBF) AML patients achieving second complete remission (CR2). However, approximately 20% of patients may relapse after transplant and donor...
17.
Hughes S, McMullan C, Aiyegbusi O, Shaw K, Kinsella F, Ferguson P, et al.
BMJ Open
. 2024 Mar;
14(3):e085392.
PMID: 38553074
Introduction: Chimeric antigen receptor (CAR) T-cell therapies are novel, potentially curative therapies for haematological malignancies. CAR T-cell therapies are associated with severe toxicities, meaning patients require monitoring during acute and...
18.
Bazarbachi A, Labopin M, Moukalled N, Kroger N, Rautenberg C, Schetelig J, et al.
Clin Cancer Res
. 2024 Mar;
30(9):1778-1787.
PMID: 38514469
Purpose: Acute myeloid leukemia (AML) is a disease of older patients. Progress in allogeneic hematopoietic cell transplantation (allo-HCT) allowed the delivery of allo-HCT to older patients. We assessed changes over...
19.
Burns D, Berlinguer-Palmini R, Werner A
Pflugers Arch
. 2024 Mar;
476(5):861-869.
PMID: 38507112
Phosphate (Pi) is an essential nutrient, and its plasma levels are under tight hormonal control. Uphill transport of Pi into cells is mediated by the two Na-dependent Pi transporter families...
20.
Paul M, Bullock K, Bailenson J, Burns D
JMIR Ment Health
. 2024 Mar;
11:e52326.
PMID: 38437873
Background: Major depressive disorder (MDD) is a global concern with increasing prevalence. While many evidence-based psychotherapies (EBPs) have been identified to treat MDD, there are numerous barriers to patients accessing...